Search Within

Howard Scher

  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (623)
  2. Meeting Abstract (460)
  3. Book Section (13)
  4. Conference Paper (11)
  5. Editorial (6)
  6. Review (6)
  7. Correspondence (2)
  8. Guidelines (2)
  9. Research Letter (2)
Groups
  1. Department of Medicine (1125)
  2. Genitourinary Oncology Service (1125)
  3. Solid Tumor Oncology Division (1125)
  4. GSK Faculty (304)
  5. Sloan Kettering Institute Faculty (248)
  6. Molecular Pharmacology and Chemistry Program Faculty (228)

More Groups

People
  1. Michael Morris (216)
  2. Susan Slovin (140)
  3. Dana Rathkopf (132)
  4. Daniel Danila (111)
  5. Steven Larson (109)
  6. Victor Reuter (97)

More People

Years
  1. 2025 (3)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (25)
  5. 2021 (19)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (325)
  2. Clinical Cancer Research (85)
  3. Cancer Research (54)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (47)
  5. Journal of Urology (36)
  6. European Urology (35)

More Publications

Publishers
  1. American Society of Clinical Oncology (332)
  2. American Association for Cancer Research (197)
  3. Elsevier Science, Inc. (119)
  4. Elsevier Inc. (72)
  5. Nature Publishing Group (58)
  6. Oxford University Press (47)

More Publishers

Results (1125)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Circulating tumor cells in prostate cancer: From discovery to clinical utility
    Review

    Pantel, K.; Hille, C.; Scher, H. I.
    Clinical Chemistry (2019)

    Fulltext@MSK | Save
  • Clonal concordance and genomic heterogeneity in single CTC copy number alterations vs. paired IMPACT metastatic tissue sequencing from mCRPC patient samples
    Meeting Abstract

    Scher, H. I.; Dago, A. E.; Lee, J.; Sutton, R.; Graf, R. P.; Schreiber, N. A.; Hullings, M.; Wang, Y.; Landers, M. A.; Solit, D. B.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Unique patterns of the selection and change in circulating tumor cell (CTC) phenotypes and genotypes by drug class in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Schonhoft, J.; Graf, R. P.; Dago, A. E.; Lee, J.; Sutton, R.; Schreiber, N. A.; Hullings, M.; Jendrisak, A.; Wang, Y.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • An integrated medical oncology-psychiatry practice model improves overall patient functionality of prostate cancer patients by identifying, quantifying and treating the pre-existing non-cancer co-morbidities
    Meeting Abstract

    Ruppert, L. M.; Dayan, E. S.; Bacharach, A.; Scher, H. I.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Autio, K. A.; Antonarakis, E. S.; Cheng, H. H.; Arauz, G.; Slack, A.; Hullings, M.; Scher, H. I.; Feng, F. Y.; Knudsen, K. E.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa)
    Meeting Abstract

    McBride, S. M.; Zelefsky, M. J.; Spratt, D. E.; Kollmeier, M.; Slovin, S. F.; Aghalar, J.; Hearn, J. W.; Den, R. B.; Deville, C.; Borofsky, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP plus D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP)
    Meeting Abstract

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Vaishampayan, U. N.; Shevrin, D. H.; Harrison, M. R.; Tagawa, S. T.; Milowsky, M. I.; Graff, J. N.; Beer, T. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E)
    Meeting Abstract

    Armstrong, A. J.; Halabi, S.; Luo, J.; Nanus, D. M.; Giannakakou, P.; Szmulewitz, R. Z.; Danila, D. C.; Healy, P.; Anand, M.; Rothwell, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Microsatellite instability in prostate cancer and response to immune checkpoint blockade
    Meeting Abstract

    Abida, W.; Cheng, M. L.; Armenia, J.; Middha, S.; Autio, K. A.; Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Carbone, E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials
    Meeting Abstract

    Pond, G. R.; Sonpavde, G.; Fizazi, K.; De Bono, J. S.; Basch, E. M.; Scher, H. I.; Smith, M. R.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save